This trial is testing a new cancer treatment to see if it is safe and effective for people with advanced pancreatic cancer.
1 Primary · 0 Secondary · Reporting Duration: 1 year
Experimental Treatment
7 Total Participants · 1 Treatment Group
Primary Treatment: anti-EGFR-bispecific antibody armed activated T-cells · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:New York | 20.0% |
Texas | 20.0% |
California | 20.0% |
Other | 40.0% |
18 - 65 | 100.0% |
University of Virginia (Specimen Analysis) | 100.0% |
Met criteria | 100.0% |